BNF for Children 2021-2022: September 2021-22

Product Information

Cefixime [update to include dosing in children from 12 years old for uncomplicated gonorrhoea and disseminated gonococcal infection]. This update contains 4 significant changes, 1 dose change, 1 new preparation, 1 deleted monograph and 2 deleted preparations. BNFC.org". Archived from the original on 20 December 2007 . Retrieved 2006-09-07. British National Formulary for Children

British National Formulary for Children - editorial staff". BNFC. NICE . Retrieved 21 January 2021. Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions [MHRA/CHM advice].COVID-19 vaccine: update to Pfizer/BioNTech vaccine ( Comirnaty®) to include use in children from 6 months old. Quinolones: reminder of the risk of disabling and potentially long-lasting or irreversible side effects [MHRA/CHM advice] (see example in ciprofloxacin). Vaccines update [classifications changed to Vaccines, live or Vaccines, inactivated and non-replicating].

a b c d e "BNF Publications - Books". www.bnf.org. BMJ Group and Royal Pharmaceutical Society. Archived from the original on 17 August 2016 . Retrieved 16 August 2016. The BNF also includes the Nurse Prescribers' Formulary (NPF) and other NPF content for use by District Nurses and Specialist Community Public Health Nurses (including Health Visitors), who have received training to become nurse prescribers. [19] Sister publications [ edit ] Wade, O. L.; McDevitt, G. D. (1966). "Prescribing and the British National Formulary". British Medical Journal. 2 (5514): 635–637. doi: 10.1136/bmj.2.5514.635. PMC 1943465. PMID 20791099.

Controlled drugs and drug dependence: updated guidance on prescription requirements for Schedule 2 and 3 Controlled Drugs. Kendall, MJ (2009). "Chairman of the Joint Formulary Committee, British National Formulary". Clinical Medicine. 9 (4): 349–352. doi: 10.7861/clinmedicine.9-4-349. PMC 4952503. PMID 19728509.

Vaccination, general principles: updated guidance on vaccination during pregnancy and breast-feeding. A new edition of the BNF book is published twice-yearly, in March and September. [1] The current edition is 85, which was published in March 2023. It is a tradition that the colour of each new edition is radically different from the previous. [2] Availability [ edit ] Valproate: reminder of current Pregnancy Prevention Programme requirements; information on new safety measures to be introduced in the coming months [MHRA/CHM advice] (advice in sodium valproate, valproic acid; see example in sodium valproate). BNF - NHS Evidence - Search Engine for Evidence in Health and Social Care". Archived from the original on 1 October 2012 . Retrieved 2012-06-14. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality [MHRA/CHM advice] (advice in abrocitinib, tofacitinib, upadacitinib; see example in tofacitinib).

This update contains 7 significant changes, 2 dose changes, 2 new monographs, 1 new preparation, and 1 deleted monograph. Specialist drug” monographs within BNF Publications: identification and reduced level of detail, see How to use BNF Publications online.

Council awards honorary membership to past chairman of the Joint Formulary Committee". The Pharmaceutical Journal. 283: 429. 2009 . Retrieved 20 January 2021. Genital system infections, antibacterial therapy: addition of an overview section, and updated guidance for the management of syphilis. Ceftriaxone [update to include dosing in children from 12 years old for gonococcal conjunctivitis, gonococcal epididymo-orchitis, and disseminated gonococcal infection]. It is provided to NHS staff - usually through their employer, but may be accessed online through MedicinesComplete. [10]Wade, O. L. (1993). "British National Formulary: Its birth, death, and rebirth". BMJ (Clinical Research Ed.). 306 (6884): 1051–1054. doi: 10.1136/bmj.306.6884.1051. PMC 1676980. PMID 8490505. This update contains 11 significant changes, 7 dose changes, 1 classification change, 3 new monographs, and 1 new preparation.